Taking metformin and Wegovy together: what the evidence says

Why these two medicines end up prescribed together so often

Metformin is one of the most widely prescribed medicines in the UK. It reduces the amount of glucose the liver releases and improves how the body responds to insulin. Wegovy (the brand name for once-weekly semaglutide) is a GLP-1 receptor agonist: it mimics a gut hormone that slows stomach emptying, reduces appetite, and prompts the pancreas to release insulin in response to food. These are genuinely distinct mechanisms. Neither drug switches the other off, and there is no interaction listed between them in standard UK prescribing references.

Because type 2 diabetes is often the condition that brings both into the picture, millions of patients worldwide have taken the two together. The large STEP clinical trials that supported Wegovy's licensing specifically enrolled participants who were on background medicines including metformin, so the combination is not an unknown quantity — it has been observed in controlled conditions at scale. The NHS medicines page for semaglutide lists the medicines that do require caution when combined with it; metformin does not appear among them as a direct interaction concern.

For people using metformin primarily for weight management (sometimes prescribed off-label for prediabetes or polycystic ovary syndrome) the question of whether adding Wegovy adds meaningful benefit is one a prescriber weighs case by case. If you are curious about taking both at the same time practically, the short answer is that there is no timing restriction between them, but you still need a full clinical assessment to proceed.

The gastrointestinal overlap, the one practical concern worth planning for

Honesty first: this is the part most people wish someone had flagged before they started. Both metformin and semaglutide carry a well-documented GI side-effect profile. Metformin's most common complaints are nausea, diarrhoea and stomach cramps, especially at higher doses and with immediate-release formulations. Wegovy's side effects are similarly GI-led: nausea, vomiting, loose stools and constipation all appear in the clinical trial data, typically most noticeable in the first few weeks or after a dose step.

Running them together does not create a new dangerous interaction, but it can stack the discomfort, particularly in the first weeks of treatment. Your prescriber may discuss the timing of any dose changes, whether extended-release metformin suits you better, and how to eat in a way that keeps symptoms manageable. The semaglutide overview has more detail on how the GI effects typically evolve. If symptoms become severe or persistent, your prescriber or the Patient Information Leaflet is your first port of call, not dose self-adjustment.

One thing worth knowing: semaglutide slows gastric emptying, which can theoretically affect how quickly any oral medicine is absorbed. For metformin this is generally not clinically significant, but it is part of the broader medication review a prescriber carries out. That review matters, which is why the two drugs are entirely separate medicines and require separate prescriptions.

Semaglutide and metformin together specifically for weight loss

If your goal is weight management rather than (or alongside) diabetes control, the picture shifts slightly. Wegovy holds a UK licence for weight management; metformin does not, and its use for weight loss is off-label. That does not make combining them wrong, but it does mean the clinical framing changes.

The trial evidence for semaglutide and metformin together for weight loss is less neat than the diabetes data. Most large weight-management trials, including STEP 1, either excluded metformin users or did not report metformin subgroup results separately in ways that have been widely published. What the data consistently show is that semaglutide 2.4mg produces substantial average weight reduction in its own right, around 15% over 68 weeks in STEP 1, published in the New England Journal of Medicine. Whether metformin adds to that effect in people without diabetes is not clearly established. A prescriber may continue metformin for its primary indication while Wegovy handles the weight-management aim, or they may review whether metformin is still needed at all as your metabolic picture changes.

If cost is part of your thinking, our Wegovy pricing page sets out what private treatment typically involves. And if you want to explore what weight-loss treatment looks like more broadly, that is a useful starting point before a consultation.

What happens at a clinical review when you are already on metformin

If you come to a prescriber already taking metformin (whether for diabetes, prediabetes or another reason) they will want to know the dose, how long you have been on it, and how well you have tolerated it. This is not a barrier to Wegovy; it is just part of the picture. You are likely in good company: a large proportion of people who start Wegovy through private clinics in the UK are already on one or more medicines.

The prescriber will check whether the conditions prompting metformin use also make you eligible for Wegovy, whether any dose adjustments are sensible as semaglutide takes effect, and whether your blood glucose will need closer monitoring given that both medicines affect insulin sensitivity. Transfer patients or those on existing treatment can provide evidence of their current regimen during the consultation process. It is also worth knowing that metformin and semaglutide are quite different drugs despite sometimes being prescribed for overlapping conditions, understanding the distinction helps you have a more informed conversation.

Our prescribers at nume carry out a same-day clinical review for every consultation, reading your full health history rather than processing a form. If you are ready to have that conversation, speak to our prescribers and get a clear answer based on your actual situation.